The Reuters Pharma 2023 event is live in Barcelona and pharmaphorum is on site to provide readers with rolling coverage of the speakers and concepts as unfolds over the next few days.
Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho